The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 19, 2019
Filed:
Jul. 21, 2017
Applicant:
Allergan, Inc., Irvine, CA (US);
Inventors:
Richard L. Beard, Newport Beach, CA (US);
John E. Donello, Dana Point, CA (US);
Veena Viswanath, Irvine, CA (US);
Assignee:
ALLERGAN, INC., Irvine, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/66 (2006.01); A61K 31/554 (2006.01); A61K 31/47 (2006.01); A61K 31/42 (2006.01); A61K 31/41 (2006.01); A61K 31/415 (2006.01); C07F 9/40 (2006.01); C07C 235/82 (2006.01); C07C 275/42 (2006.01); C07D 217/24 (2006.01); C07D 223/10 (2006.01); C07D 233/02 (2006.01); C07D 235/02 (2006.01); C07D 257/04 (2006.01); C07D 261/12 (2006.01); C07D 401/06 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 405/06 (2006.01); C07D 409/06 (2006.01); A61K 9/00 (2006.01); A61K 31/17 (2006.01); A61K 31/196 (2006.01); A61K 31/4166 (2006.01); A61K 31/662 (2006.01);
U.S. Cl.
CPC ...
C07F 9/40 (2013.01); A61K 9/0048 (2013.01); A61K 31/17 (2013.01); A61K 31/196 (2013.01); A61K 31/4166 (2013.01); A61K 31/42 (2013.01); A61K 31/662 (2013.01); C07C 235/82 (2013.01); C07C 275/42 (2013.01); C07D 217/24 (2013.01); C07D 223/10 (2013.01); C07D 233/02 (2013.01); C07D 235/02 (2013.01); C07D 257/04 (2013.01); C07D 261/12 (2013.01); C07D 401/06 (2013.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 405/06 (2013.01); C07D 409/06 (2013.01); A61K 9/0019 (2013.01);
Abstract
The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.